Natera, Inc. (NASDAQ:NTRA) Shares Acquired by OMERS ADMINISTRATION Corp

OMERS ADMINISTRATION Corp increased its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 53.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,300 shares of the medical research company's stock after buying an additional 2,200 shares during the period. OMERS ADMINISTRATION Corp's holdings in Natera were worth $997,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in NTRA. Principal Securities Inc. increased its position in Natera by 20.7% during the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock valued at $54,000 after purchasing an additional 59 shares during the period. Gladstone Institutional Advisory LLC increased its position in Natera by 1.7% during the 4th quarter. Gladstone Institutional Advisory LLC now owns 3,629 shares of the medical research company's stock valued at $574,000 after purchasing an additional 61 shares during the period. Silver Oak Securities Incorporated increased its position in Natera by 3.1% during the 4th quarter. Silver Oak Securities Incorporated now owns 2,963 shares of the medical research company's stock valued at $470,000 after purchasing an additional 89 shares during the period. Colonial Trust Co SC increased its position in Natera by 7.8% during the 4th quarter. Colonial Trust Co SC now owns 1,325 shares of the medical research company's stock valued at $210,000 after purchasing an additional 96 shares during the period. Finally, Blue Trust Inc. increased its position in Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock valued at $30,000 after purchasing an additional 97 shares during the period. Hedge funds and other institutional investors own 99.90% of the company's stock.

Natera Stock Up 0.6%

Shares of NASDAQ:NTRA traded up $0.84 during trading on Friday, reaching $153.32. The stock had a trading volume of 1,085,198 shares, compared to its average volume of 1,389,879. The firm's 50-day simple moving average is $149.39 and its 200 day simple moving average is $157.51. The company has a market capitalization of $20.94 billion, a P/E ratio of -87.11 and a beta of 1.79. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. Natera, Inc. has a one year low of $92.14 and a one year high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last released its earnings results on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, topping analysts' consensus estimates of ($0.59) by $0.09. The company had revenue of $501.83 million during the quarter, compared to analysts' expectations of $446.68 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. Natera's revenue for the quarter was up 36.5% on a year-over-year basis. During the same period last year, the business earned ($0.56) EPS. As a group, research analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Insider Buying and Selling

In other Natera news, insider Solomon Moshkevich sold 2,206 shares of Natera stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $152.18, for a total transaction of $335,709.08. Following the completion of the sale, the insider now directly owns 139,280 shares in the company, valued at approximately $21,195,630.40. The trade was a 1.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Gail Boxer Marcus sold 4,000 shares of Natera stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $151.61, for a total transaction of $606,440.00. Following the sale, the director now owns 9,704 shares of the company's stock, valued at approximately $1,471,223.44. The trade was a 29.19% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 152,436 shares of company stock worth $22,019,079 in the last three months. Corporate insiders own 7.60% of the company's stock.

Wall Street Analyst Weigh In

NTRA has been the topic of a number of research reports. Morgan Stanley raised their target price on shares of Natera from $176.00 to $185.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Piper Sandler raised their target price on shares of Natera from $205.00 to $210.00 and gave the company an "overweight" rating in a research report on Thursday, May 15th. Canaccord Genuity Group reissued a "buy" rating and set a $180.00 target price on shares of Natera in a research report on Wednesday, February 26th. BTIG Research reissued a "buy" rating on shares of Natera in a research report on Friday, February 28th. Finally, The Goldman Sachs Group raised their price target on shares of Natera from $160.00 to $190.00 and gave the company a "buy" rating in a report on Tuesday, January 28th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $182.12.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.